Skip to content
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology

Understanding Coronary Stenosis and Heart Disease

At a Glance

Coronary stenosis develops when atherosclerotic plaque and inflammation narrow the heart’s arteries, but ischemia can also result from tiny-vessel dysfunction or vasospasm. A “clear” angiogram does not always rule out heart ischemia.

Coronary stenosis is a narrowing of the arteries that supply blood to your heart. It is one of the most common medical conditions worldwide, affecting approximately 197 million people globally [1]. In the United States alone, over 17 million people live with coronary artery disease [2]. While it is common, it is also highly complex. It is no longer viewed as just a “clogged pipe” but rather as a dynamic biological process involving inflammation, cholesterol, and the unique health of your blood vessel walls [3][4].

The Biological Roots: How Blockages Form

The process that leads to stenosis is called atherosclerosis—the buildup of fats, cholesterol, and other substances in and on your artery walls. This process is not just a passive accumulation of debris. It involves several active biological steps:

  • Endothelial Dysfunction: The endothelium is the thin inner lining of your blood vessels. It acts like a smart barrier, controlling how blood flows. When this lining is damaged by factors like smoking, high blood pressure, or high blood sugar, it becomes “leaky” [3].
  • LDL and ApoB Retention: Low-density lipoprotein (LDL), often called “bad” cholesterol, carries particles that get trapped inside the damaged artery wall. Recent research highlights that the number of these particles (often measured as ApoB) and how long they stay there are primary drivers of plaque growth [3].
  • Inflammation: Once these particles are trapped, your immune system views them as intruders. White blood cells (macrophages) rush to the area to clear the cholesterol, but they often become overwhelmed and turn into “foam cells” [4][5]. This creates a state of persistent inflammation that causes the plaque to grow and change over time [6].

More Than Just a Fixed Pipe: The Dynamic Nature of Plaque

Arterial plaques are living, changing structures. They do not just sit there; they remodel and evolve:

  • Remodeling: Sometimes, as a plaque grows, the artery wall actually bulges outward to keep the channel for blood flow open. This is called “positive remodeling.” While it maintains blood flow for a time, these plaques can sometimes be more vulnerable [7].
  • Calcification: Over time, plaques may develop calcium deposits. While small, “spotty” calcification is sometimes associated with unstable plaques, extensive, dense calcification often indicates an older plaque. However, a heavily calcified plaque is not guaranteed to be safe; plaque characterization on scans informs treatment but does not replace clinical assessment [8][9].
  • Rupture vs. Erosion: A plaque “ruptures” when its thin fibrous cap breaks, exposing the inside to the blood. This can trigger a blood clot [10]. Plaque “erosion” is a different process where the surface of the plaque wears away; both can lead to sudden heart events [11].

Navigating the Terminology: CAD, IHD, and INOCA

You may hear several terms used to describe your heart health. While they overlap, they have distinct meanings:

  • Coronary Artery Disease (CAD): This specifically refers to the presence of atherosclerotic plaques in the large (epicardial) arteries of the heart [12].
  • Ischemic Heart Disease (IHD): This is a broader “umbrella” term. It refers to any situation where the heart muscle isn’t getting enough oxygen-rich blood, whether caused by a large blockage or a problem with the tiny vessels [12][13].
  • INOCA (Ischemia with Non-Obstructive Coronary Arteries): This occurs when a patient has objective evidence of heart ischemia but tests show no major (obstructive) blockages in the large arteries [13][14].

The Importance of INOCA and CMD

For many years, patients who had chest pain but “clear” large arteries on an angiogram were told nothing was wrong. We now know that many of these patients have Coronary Microvascular Dysfunction (CMD)—a condition where the tiny microscopic vessels that branch off the main arteries don’t expand properly—or vasospasm [15][16].

INOCA is significantly more common in women than in men. Among people undergoing certain heart imaging for chest pain, INOCA is found in up to 65% of women compared to about 30% of men [17][18]. It is a real condition that can significantly impact quality of life and requires its own specific management strategies [14].

Stable vs. Acute: Two Sides of the Condition

Doctors categorize coronary conditions into two main types based on how they present:

  1. Chronic Coronary Syndromes (CCS): Formerly called “stable CAD,” this is characterized by predictable symptoms, like chest pain that only happens during exercise and goes away promptly with rest. It usually involves a fixed narrowing that limits blood flow only when the heart works hard [19][20].
  2. Acute Coronary Syndromes (ACS): This is a medical emergency. It happens when an acute reduction in coronary blood flow occurs, such as when a plaque suddenly ruptures or erodes, leading to a blood clot. This includes conditions like unstable angina and heart attacks [11][21].

Understanding whether your condition is a stable, chronic process or an acute, sudden event is the first step in determining your care plan. Progress in cardiology now allows doctors to look beyond the percentage of narrowing to help assess the actual “activity” and “vulnerability” of the plaques themselves, though this imaging informs rather than replaces careful clinical evaluation [22][23].

Common questions in this guide

What is coronary stenosis, and what causes the narrowing?
Coronary stenosis is a narrowing of the arteries that carry blood to the heart. It usually develops through atherosclerosis, in which cholesterol-containing particles collect in the artery wall and trigger ongoing inflammation. Damage from smoking, high blood pressure, or high blood sugar can promote this process.
Can I have heart ischemia if my angiogram shows no major blockage?
Yes. Ischemia can occur without a major blockage in the large coronary arteries, a pattern called INOCA. Causes may include coronary microvascular dysfunction, in which tiny vessels do not widen properly, or coronary artery spasm. This is a real condition that can affect quality of life and needs medical evaluation.
How are stable coronary disease and acute coronary syndrome different?
Chronic or stable coronary disease usually causes predictable chest pain during exertion that improves with rest because a fixed narrowing limits flow when the heart works harder. Acute coronary syndrome occurs when blood flow suddenly falls, often after a plaque ruptures or erodes and a clot forms. It includes unstable angina and heart attacks and is a medical emergency.
Does the percentage of artery narrowing tell me how dangerous my plaque is?
Not by itself. Plaques can grow, bulge outward, become calcified, rupture, or erode, and a smaller or less obvious plaque can still be biologically active. Imaging can help characterize plaque, but clinicians interpret those findings together with symptoms and other clinical information.
What do CAD, IHD, and INOCA mean?
CAD means atherosclerotic plaque is present in the large coronary arteries. IHD is a broader term for any situation in which the heart muscle does not receive enough oxygen-rich blood. INOCA means there is objective evidence of ischemia even though tests show no major blockage in the large arteries.
Why should I ask about LDL, ApoB, and blood pressure?
LDL cholesterol and ApoB-containing particles can become trapped in a damaged artery wall and contribute to plaque growth, while high blood pressure can injure the vessel lining. Ask your clinician how your current levels, how long they have been elevated, and other conditions such as diabetes affect your cardiovascular risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current percentage of stenosis in my coronary arteries, and do I have 'obstructive' or 'non-obstructive' disease?
  2. 2.Is my heart pain (angina) likely caused by a fixed blockage or by a functional issue like microvascular dysfunction?
  3. 3.Beyond the degree of narrowing, what do my tests say about the overall burden of plaque in my arteries?
  4. 4.If my arteries show no major blockages, could I still have INOCA or another condition that affects the smaller vessels?
  5. 5.Given my diagnosis, do we need to check for signs of inflammation or specific cholesterol particles like ApoB or LDL?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.

    Roth GA, Mensah GA, Johnson CO, et al.

    Journal of the American College of Cardiology 2020; (76(25)):2982-3021 doi:10.1016/j.jacc.2020.11.010.

    PMID: 33309175
  2. 2

    Magnetocardiography for the diagnosis of non-obstructive coronary artery disease1.

    Shin ES, Park JW, Lim DS

    Clinical hemorheology and microcirculation 2018; (69(1-2)):9-11 doi:10.3233/CH-189106.

    PMID: 29758933
  3. 3

    Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies.

    Ference BA

    Cardiology clinics 2018; (36(2)):203-211 doi:10.1016/j.ccl.2017.12.001.

    PMID: 29609749
  4. 4

    The immunology of atherosclerosis.

    Gisterå A, Hansson GK

    Nature reviews. Nephrology 2017; (13(6)):368-380 doi:10.1038/nrneph.2017.51.

    PMID: 28392564
  5. 5

    Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation.

    Schwarz N, Fernando S, Chen YC, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023; (37(4)):e22846 doi:10.1096/fj.202201469R.

    PMID: 36856983
  6. 6

    Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?

    Rakocevic J, Dobric M, Borovic ML, et al.

    Reviews in cardiovascular medicine 2023; (24(1)):10 doi:10.31083/j.rcm2401010.

    PMID: 39076864
  7. 7

    Cardiac CT in Non-Obstructive Coronary Artery Disease (NOCAD): A Literature Review.

    Meossi S, Izzo C, Rotondo L, et al.

    Journal of clinical medicine 2025; (15(1)) doi:10.3390/jcm15010032.

    PMID: 41517282
  8. 8

    Coronary Artery Calcification and its Progression: What Does it Really Mean?

    Mori H, Torii S, Kutyna M, et al.

    JACC. Cardiovascular imaging 2018; (11(1)):127-142 doi:10.1016/j.jcmg.2017.10.012.

    PMID: 29301708
  9. 9

    Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research.

    Gaba P, Gersh BJ, Muller J, et al.

    Nature reviews. Cardiology 2023; (20(3)):181-196 doi:10.1038/s41569-022-00769-8.

    PMID: 36151312
  10. 10

    Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.

    Yahagi K, Kolodgie FD, Otsuka F, et al.

    Nature reviews. Cardiology 2016; (13(2)):79-98 doi:10.1038/nrcardio.2015.164.

    PMID: 26503410
  11. 11

    Platelet biology and function: plaque erosion vs. rupture.

    Baaten CCFMJ, Nagy M, Bergmeier W, et al.

    European heart journal 2024; (45(1)):18-31 doi:10.1093/eurheartj/ehad720.

    PMID: 37940193
  12. 12

    Myocardial Ischemic Syndromes: A New Nomenclature to Harmonize Evolving International Clinical Practice Guidelines.

    Boden WE, De Caterina R, Kaski JC, et al.

    Circulation 2024; (150(20)):1631-1637 doi:10.1161/CIRCULATIONAHA.123.065656.

    PMID: 39210827
  13. 13

    Challenges in diagnosing coronary microvascular dysfunction and coronary vasospasm.

    Burgess S, Cader FA, Gulati M, et al.

    Cardiovascular revascularization medicine : including molecular interventions 2025; (76()):17-24 doi:10.1016/j.carrev.2025.04.025.

    PMID: 40312200
  14. 14

    An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

    Kunadian V, Chieffo A, Camici PG, et al.

    European heart journal 2020; (41(37)):3504-3520 doi:10.1093/eurheartj/ehaa503.

    PMID: 32626906
  15. 15

    Novel diagnostic approaches and management of coronary microvascular dysfunction.

    Pompei G, Ganzorig N, Kotanidis CP, et al.

    American journal of preventive cardiology 2024; (19()):100712 doi:10.1016/j.ajpc.2024.100712.

    PMID: 39161975
  16. 16

    Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy.

    Dean J, Cruz SD, Mehta PK, Merz CN

    Nature reviews. Cardiology 2015; (12(7)):406-14 doi:10.1038/nrcardio.2015.72.

    PMID: 26011377
  17. 17

    A Practical Approach to Invasive Testing in Ischemia With No Obstructive Coronary Arteries (INOCA).

    Bastiany A, Pacheco C, Sedlak T, et al.

    CJC open 2022; (4(8)):709-720 doi:10.1016/j.cjco.2022.04.009.

    PMID: 36035733
  18. 18

    Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis.

    Mileva N, Nagumo S, Mizukami T, et al.

    Journal of the American Heart Association 2022; (11(7)):e023207 doi:10.1161/JAHA.121.023207.

    PMID: 35301851
  19. 19

    The Pathophysiology of Myocardial Ischemia and Perioperative Myocardial Infarction.

    Smit M, Coetzee AR, Lochner A

    Journal of cardiothoracic and vascular anesthesia 2020; (34(9)):2501-2512 doi:10.1053/j.jvca.2019.10.005.

    PMID: 31685419
  20. 20

    Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.

    Guarini G, Huqi A, Morrone D, Marzilli M

    Cardiovascular drugs and therapy 2016; (30(4)):379-391 doi:10.1007/s10557-016-6677-y.

    PMID: 27497930
  21. 21

    Diagnosis and Treatment of Acute Coronary Syndromes: A Review.

    Bhatt DL, Lopes RD, Harrington RA

    JAMA 2022; (327(7)):662-675 doi:10.1001/jama.2022.0358.

    PMID: 35166796
  22. 22

    The Role of Cardiac Computed Tomography Angiography in Risk Stratification for Coronary Artery Disease.

    van Rosendael SE, Shiyovich A, Cardoso RN, et al.

    Journal of the Society for Cardiovascular Angiography & Interventions 2024; (3(11)):102230 doi:10.1016/j.jscai.2024.102230.

    PMID: 39649823
  23. 23

    Artificial intelligence-enabled plaque characterization from coronary computed tomography establishes basis of angina in women with nonobstructive atherosclerosis.

    Wolny R, Flores Tomasino G, Grodecki K, et al.

    Communications medicine 2026; (6(1)).

    PMID: 42209864

This page is for informational purposes only and does not constitute medical advice. A cardiologist or other qualified clinician should interpret your symptoms, risk factors, and heart-test results.

Get notified when new evidence is published on coronary stenosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.